Sickle Cell Crisis: Comprehensive Guide for U.S. Paramedics

Normal vs. Pathological Anatomy and Physiology

Normal Hemoglobin Structure

Normal adult hemoglobin (HbA) consists of two alpha and two beta globin chains (α2β2) bound to heme molecules. When oxygen binds to heme, the hemoglobin molecule changes shape to facilitate efficient oxygen binding and release, maintaining flexible, disc-shaped red blood cells that flow smoothly through capillaries 1.

Pathological Changes in Sickle Cell Disease

In sickle cell disease, a single genetic mutation replaces glutamic acid with valine at position 6 of the beta globin gene, creating abnormal hemoglobin S (HbS). When HbS becomes deoxygenated, it forms rigid polymers that distort red blood cells into the characteristic sickle or crescent shape 1.

The core pathophysiology involves a vicious cycle:

Polymerization: HbS molecules form long chains when deoxygenated, causing red cells to sickle
Sickling-unsickling cycle: As cells travel to peripheral tissues and return to lungs, they continuously sickle and un-sickle. If return to the lungs is delayed, polymerization becomes more extensive 1
Membrane damage: Extensive polymerization damages the red cell membrane and cytoskeleton, creating irreversibly sickled cells
Hemolysis: Damaged cells are destroyed by the spleen and liver, causing chronic anemia (typical hemoglobin 60-90 g/L in severe disease) 1
Vascular adhesion: Damaged red cell membranes stick to blood vessel walls, causing vaso-occlusion
Ischemia-reperfusion injury: Blocked vessels cause tissue oxygen deprivation and subsequent damage when blood flow returns
Nitric oxide depletion: Intravascular hemolysis releases free hemoglobin that consumes nitric oxide, worsening blood vessel damage 1

This repeated cycle of hemolysis, ischemia, and inflammation produces both acute crises and chronic organ damage 1.

Demographics and Pertinent History

Common Demographics

Sickle cell disease predominantly affects individuals of African or Caribbean descent (98% of U.S. patients), with approximately 100,000 people living with SCD in the United States 1, 2. The disease also occurs in families from the Middle East, India, and the Mediterranean region 1.

Why these demographics? The sickle cell gene evolved in malaria-endemic regions because carriers (sickle cell trait) have partial protection against malaria. This selective advantage led to higher gene frequencies in populations from sub-Saharan Africa, the Mediterranean, Middle East, and India 1.

Critical History Elements

When encountering a potential sickle cell crisis patient, obtain:

Known diagnosis: Most U.S. patients born after 2006 were diagnosed through newborn screening 1
Baseline hemoglobin: Severe forms (HbSS, HbSβ0-thalassemia) typically run 60-90 g/L; moderate forms (HbSC) run higher 1
Crisis frequency: Patients with frequent crises (≥2-3 per year) have more severe disease 3
Current medications: Hydroxyurea, L-glutamine, penicillin prophylaxis (see medications section)
Recent triggers: Dehydration, infection, cold exposure, stress, high altitude, alcohol use
Baseline pain level: Many patients have chronic pain; assess change from baseline
Previous complications: History of stroke, acute chest syndrome, priapism, avascular necrosis
Last transfusion: Recent transfusions affect management decisions

Signs and Symptoms: Early vs. Late Findings

Early Assessment Findings (Vaso-Occlusive Crisis Beginning)

Pain characteristics:

Severe, sudden-onset pain in bones, joints, chest, or abdomen
Pain often described as deep, throbbing, or stabbing
Most commonly affects long bones, back, chest, and abdomen
Patient may report this feels like their "usual crisis" or different from baseline chronic pain

Vital signs (early):

Mild tachycardia (compensating for chronic anemia)
Normal or slightly elevated blood pressure
Normal respiratory rate initially
Low-grade fever possible (but always consider infection as trigger)

Physical examination (early):

Patient appears uncomfortable but alert
Localized tenderness over affected bones/joints
No obvious swelling initially
Skin may appear pale or jaundiced (chronic finding from hemolysis)
Capillary refill may be normal or slightly delayed

Late/Severe Assessment Findings (Complications Developing)

Acute Chest Syndrome (life-threatening):

New onset chest pain, cough, dyspnea
Tachypnea (respiratory rate >20-24)
Hypoxia (SpO2 <95% on room air)
Fever
Crackles or decreased breath sounds on auscultation
This is a medical emergency requiring immediate transport 1

Severe vaso-occlusive crisis:

Extreme pain unresponsive to patient's home medications
Altered mental status (suggests stroke or severe hypoxia)
Priapism (painful, sustained erection >4 hours—urologic emergency)
Abdominal distension with severe pain (splenic sequestration or infarction)
Signs of shock: hypotension, tachycardia >120, cool/clammy skin, altered mental status

Stroke signs:

Facial droop, arm weakness, speech difficulty
Sudden severe headache
Vision changes
Seizures
Stroke occurs in up to 10% of children with SCD; requires emergent transport 1

Infection/sepsis:

Fever >38.5°C (101.3°F)
Rigors/shaking chills
Hypotension
Tachycardia out of proportion to fever
Patients with SCD have increased infection susceptibility due to functional asplenia 1

EMS Management: Scene to Hospital Transfer

Initial Scene Assessment (First 60 Seconds)

Scene safety and general impression
Primary survey: Airway, breathing, circulation
Rapid history: "Do you have sickle cell disease? Is this your usual crisis? What medications do you take?"
Vital signs: Include pulse oximetry (critical for detecting hypoxia)

Immediate Interventions

Oxygen therapy:

Apply supplemental oxygen if SpO2 <95% or any respiratory distress
Target SpO2 ≥95% to prevent further sickling
Even if SpO2 is normal, consider oxygen if patient has chest pain or dyspnea

IV access and hydration:

Establish large-bore IV (18-gauge or larger if possible)
Begin normal saline at 150-250 mL/hour (adjust for patient size)
Dehydration worsens sickling by increasing blood viscosity 1
Avoid over-hydration in patients with acute chest syndrome (risk of pulmonary edema)

Pain management (critical):

Administer opioid analgesia rapidly—delays worsen outcomes
Morphine 0.1 mg/kg IV (typical adult dose 5-10 mg) or fentanyl 1-2 mcg/kg IV
Reassess pain every 5-10 minutes; repeat dosing as needed per protocol
Do not withhold opioids due to addiction concerns—SCD patients are not at higher risk for addiction than general population 2
Document pain score (0-10 scale) before and after medication

Temperature management:

Keep patient warm (cold triggers sickling)
Remove wet clothing
Use blankets during transport

Transport Decision Algorithm

Immediate transport (lights and sirens) for:

Acute chest syndrome (chest pain + dyspnea + hypoxia)
Stroke symptoms
Altered mental status
Priapism >2-4 hours
Signs of sepsis/severe infection
Severe abdominal pain with distension (splenic sequestration)
Hypotension or shock
Uncontrolled pain despite prehospital opioids

Routine transport (still required) for:

Typical vaso-occlusive pain crisis
Pain requiring parenteral opioids
Fever without sepsis signs
Any crisis not responding to home management

Consider non-transport only if:

Patient explicitly refuses (document thoroughly)
Pain controlled with oral medications at home
No fever, hypoxia, or concerning symptoms
Patient has reliable follow-up plan
However, most protocols require transport for any sickle cell crisis call

En Route Care

Continuous monitoring:

Vital signs every 5 minutes if unstable, every 15 minutes if stable
Continuous pulse oximetry
Cardiac monitoring (arrhythmias possible with severe anemia)
Reassess pain score

Ongoing interventions:

Continue IV fluids
Repeat pain medication as needed
Maintain oxygen therapy
Keep patient warm
Position of comfort (often semi-Fowler's for chest pain)

Hospital notification:

Alert receiving facility for sickle cell crisis
Report vital signs, oxygen saturation, pain score
Notify if acute chest syndrome, stroke, or sepsis suspected
Report medications administered and response

Chronic Medications: What Patients May Already Be Taking

Hydroxyurea (Hydroxycarbamide)

What it does: Increases fetal hemoglobin (HbF) levels, which prevents HbS polymerization. This is the first-line disease-modifying therapy and has been standard since 1998 1, 2.

Mechanism: HbF (normally present only in fetuses) doesn't participate in sickling. By raising HbF from <5% to >8%, hydroxyurea reduces sickling frequency 1.

Clinical effect: Reduces painful crises, hospitalizations, and acute chest syndrome episodes. Patients on hydroxyurea typically have milder disease 1.

L-Glutamine (Endari)

What it does: Reduces oxidative damage to red blood cells 3.

Mechanism: Sickle red cells are more susceptible to oxidative stress. L-glutamine improves the NAD redox potential in red cells, increasing availability of reduced glutathione (an antioxidant), which protects cell membranes from damage 3.

Clinical effect: In trials, reduced sickle cell crises from median 4 to 3 per year, reduced hospitalizations from median 3 to 2 per year, and decreased hospital days from 11 to 6.5 days 3. Reduces acute chest syndrome incidence from 23% to 8.6% 3.

Dosing: Taken orally twice daily, mixed with food or beverage 3.

Crizanlizumab (Adakveo)

What it does: Prevents red blood cells from sticking to blood vessel walls 2, 4.

Mechanism: Blocks P-selectin, a protein on endothelial cells that sickle cells abnormally adhere to, reducing vaso-occlusion 4.

Clinical effect: Reduced pain crises from 2.98 to 1.63 per year in trials 2.

Important note: Removed from European market in 2023 due to efficacy concerns; remains FDA-approved in U.S. but use is declining 5.

Voxelotor (Oxbryta)

What it does: Increases hemoglobin's oxygen-binding capacity 2, 4.

Mechanism: Stabilizes oxygenated hemoglobin, preventing deoxygenation and subsequent polymerization 4.

Clinical effect: Increased hemoglobin by ≥1 g/dL in 51% of patients vs. 7% on placebo 2.

Critical update: Withdrawn from global markets in September 2024 due to higher mortality in treated patients compared to placebo 5. Patients may still be taking it if prescribed before withdrawal.

Penicillin Prophylaxis

What it does: Prevents pneumococcal infections 1.

Why needed: Repeated splenic infarctions cause functional asplenia (spleen doesn't work), making patients highly susceptible to encapsulated bacteria, especially Streptococcus pneumoniae 1.

Who takes it: All children with SCD from infancy through at least age 5 years; some continue longer 1.

Pain Medications

Many patients take chronic opioids (morphine, oxycodone, hydromorphone) for baseline chronic pain. Do not assume addiction—chronic pain is a legitimate disease manifestation 2.

Complications of Untreated Sickle Cell Crisis

Acute Complications (Hours to Days)

Acute Chest Syndrome:

Develops when sickled cells block pulmonary vessels
Causes: new pulmonary infiltrate + fever, chest pain, dyspnea, or hypoxia
Leading cause of death in adults with SCD 1
Mortality risk increases with delayed treatment
Requires immediate hospitalization, oxygen, antibiotics, possible transfusion

Stroke:

Results from cerebral vessel occlusion or hemorrhage
Can cause permanent neurological damage or death
Risk highest in children but occurs at all ages 1
Time-sensitive—requires immediate imaging and intervention

Splenic Sequestration:

Sudden trapping of blood in spleen
Causes rapid drop in hemoglobin, hypovolemic shock
Abdominal pain, distension, splenomegaly
Can be fatal within hours if untreated
More common in children (adults often have auto-splenectomy from repeated infarcts)

Priapism:

Prolonged, painful erection from penile vaso-occlusion
If >4 hours, risk of permanent erectile dysfunction
Requires urologic emergency intervention 1

Overwhelming Sepsis:

Functional asplenia makes patients susceptible to rapid, severe bacterial infections
S. pneumoniae, Haemophilus influenzae, Salmonella most common
Can progress to septic shock and death within hours
Fever in SCD patient is always an emergency 1

Chronic Complications (Months to Years)

Avascular Necrosis:

Bone death from repeated ischemia, especially femoral and humeral heads
Causes chronic pain and disability
May require joint replacement 1

Chronic Kidney Disease:

Repeated renal ischemia causes progressive nephropathy
Leads to proteinuria, hypertension, eventual renal failure 1

Pulmonary Hypertension:

Chronic hemolysis and vascular damage cause elevated pulmonary pressures
Leads to right heart failure
Associated with increased mortality 1

Retinopathy:

Retinal vessel occlusion causes vision loss
Can lead to blindness if untreated 1

Chronic Pain Syndrome:

Repeated crises and nerve damage cause persistent pain
Significantly impacts quality of life 1

Leg Ulcers:

Chronic ischemia causes non-healing wounds, typically around ankles
Difficult to treat, prone to infection 1

Mortality Impact

Without prompt treatment, sickle cell crises contribute to a life expectancy 20 years shorter than the general population 2. However, with optimal care including early crisis management, most children now survive to adulthood 1.

Key Paramedic Pitfalls to Avoid

Underestimating pain severity: Sickle cell pain is among the most severe pain conditions. Aggressive opioid analgesia is appropriate and necessary.
Delaying pain medication: Waiting until hospital arrival worsens outcomes. Treat pain immediately.
Assuming drug-seeking behavior: Patients with SCD are not at higher risk for addiction. Frequent ED visits reflect disease severity, not drug-seeking 2.
Missing acute chest syndrome: Any chest pain, cough, or dyspnea in SCD is acute chest syndrome until proven otherwise. This is life-threatening.
Ignoring fever: Even low-grade fever can indicate life-threatening sepsis in functionally asplenic patients.
Inadequate hydration: Dehydration worsens sickling. Start IV fluids early.
Allowing patient to become cold: Cold triggers sickling. Keep patient warm during transport.
Dismissing "frequent flyers": Patients with frequent crises have severe disease and are at highest risk for complications.

Have a follow-up question?